Medulloblastoma: Clinical Trials

110 trials for Medulloblastoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

57 completed, 18 active not recruiting, 12 recruiting, 12 terminated. 110 Phase 2, 27 Phase 1, 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 2110Completed 57, Active not recruiting 18, Recruiting 12, Terminated 12, Unknown 7, Withdrawn 2, Not yet recruiting 1, Suspended 1
Phase 127Completed 11, Terminated 7, Recruiting 5, Active not recruiting 2, Suspended 1, Unknown 1
Phase 32Active not recruiting 1, Completed 1

Follow Medulloblastoma: new trials by email Literature Review of Medulloblastoma trials Research Report on Medulloblastoma

Trials (filtered) newest first · largest first

All 110 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Axitinib and Oral Metronomic Etoposide for Pediatric Children and AYA Refractory/Relapsing Medulloblastoma and Ependymoma
administration of axitinib in combination with etoposide - Medulloblastoma, Ependymoma
Phase 1 / Phase 2RecruitingAssistance Publique Hopitaux De Marseille402032-02-012026-11-12
PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma
PEP-CMV vaccine, Tetanus booster, Nivolumab - Diffuse Midline Glioma, Diffuse Midline High-grade Glioma
Phase 1 / Phase 2SuspendedWashington University School of Medicine682026-11-302026-10-30
Arsenic Trioxide Combined With Chemotherapy for Relapsed SHH-Activated and/or TP53-Mutant Medulloblastoma
Arsenic Trioxide (ATO), ETOPOSIDE - Study, Cisplatin - Medulloblastoma
Phase 2Not yet recruitingSun Yat-Sen Memorial Hospital of Sun Yat-Sen University782026-10-012026-10-02
Pharmacoscopy for Patients With Refractory Primary Brain Tumors
Pharmacoscopy 1.0 - Brain (Nervous System) Cancers, Glioblastoma
Phase 2RecruitingUniversity of Zurich402026-09-112026-09-21
Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease
Liothyronine (L-T3), Bevacizumab, Irinotecan - Medulloblastoma, Medulloblastoma, Childhood
Phase 1 / Phase 2RecruitingSabine Mueller, MD, PhD692026-08-212026-09-28
Digoxin Medulloblastoma Study
Digoxin - Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH
Phase 2RecruitingH. Lee Moffitt Cancer Center and Research Institute232026-01-152026-11-04
Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
Olaparib; 177Lu-DOTATATE - Solid Tumor Cancer, Medulloblastoma
Phase 1 / Phase 2RecruitingFundación de investigación HM252024-09-202026-06-04
PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
PEP-CMV, Temozolomide, Tetanus Diphtheria Vaccine - High Grade Glioma, Diffuse Intrinsic Pontine Glioma
Phase 2RecruitingNationwide Children's Hospital1202024-07-182026-08-24
PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
PLX038 - Glioma, Medulloblastoma
Phase 1 / Phase 2RecruitingNational Cancer Institute (NCI)1462024-01-312026-11-06
Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma
Surgical resection, Ommaya/VPS, Methotrexate - Medulloblastoma
Phase 2RecruitingSt. Jude Children's Research Hospital1302022-12-202026-09-15
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
LUTATHERA® (Lutetium Lu 177 dotatate) - High Grade Glioma, Meningioma
Phase 1 / Phase 2RecruitingNationwide Children's Hospital652022-11-212026-07-20
Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma
Sonidegib, Cisplatin, Lomustine - Medulloblastoma
Phase 2TerminatedEuropean Organisation for Research and Treatment of Cancer - EORTC202022-11-112025-10-23
Quantitative Assessment of Radiation-induced Neuroinflammation - A Proof of Principle Study
[18F]DPA714 - Brain Tumor, Medulloblastoma
Phase 2Active not recruitingSt. Jude Children's Research Hospital222022-07-052026-10-19
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
ENV-101 (taladegib) - Solid Tumors With PTCH1 Loss-of-function Mutations
Phase 2CompletedEndeavor Biomedicines, Inc.202022-05-242026-03-05
131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma
Irinotecan, Temozolomide, Bevacizumab - Recurrent Medulloblastoma, Recurrent Ependymoma
Phase 2Active not recruitingPediatric Brain Tumor Consortium622022-04-042026-07-28
Fluorescence Detection of Adult Primary Central Nervous System Tumors With Tozuleristide and the Canvas System
tozuleristide, Canvas imaging system, Surgical resection of tumor - Central Nervous System Tumor
Phase 2CompletedJohn Yu502021-09-302026-07-10
177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma
177Lu-DTPA-omburtamab - Medulloblastoma, Childhood
Phase 1 / Phase 2TerminatedY-mAbs Therapeutics22021-09-302023-10-06
A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer
Nivolumab, NKTR-214 - Ependymoma, Ewing Sarcoma
Phase 1 / Phase 2TerminatedBristol-Myers Squibb152021-06-032023-03-24
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial
Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography - Hematopoietic and Lymphatic System Neoplasm, Recurrent Ependymoma
Phase 2Active not recruitingNational Cancer Institute (NCI)12021-05-032026-11-13
Clinical Trial to Assess the Safety and Efficacy of AloCELYVIR With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) in Combination With Radiotherapy or Medulloblastoma in Monotherapy
AloCELYVIR - Diffuse Intrinsic Pontine Glioma, Medulloblastoma, Childhood, Recurrent
Phase 1 / Phase 2Active not recruitingHospital Infantil Universitario Niño Jesús, Madrid, Spain132021-04-192024-12-27

Showing 20 of 110. Sign in to see all of them.

Narrower conditions

Ependymoma (43)  ·  Neuroblastoma (41)  ·  Central Nervous System Neoplasms (39)  ·  Glioma (38)  ·  Brain Neoplasms (29)  ·  Osteosarcoma (25)  ·  Astrocytoma (24)  ·  Rhabdomyosarcoma (24)  ·  Sarcoma (23)  ·  Familial ependymoma (20)  ·  Rhabdoid Tumor (20)  ·  Glioblastoma (19)  ·  Neuroectodermal Tumors, Primitive, Peripheral (19)  ·  Neuroectodermal Tumors, Primitive (18)

Broader conditions

Neoplasms by Histologic Type (110)  ·  Neoplasms, Glandular and Epithelial (110)  ·  Neoplasms, Nerve Tissue (110)  ·  Neoplasms, Neuroepithelial (109)  ·  Neuroectodermal Tumors (107)  ·  Neoplasms (104)  ·  Neoplasms, Germ Cell and Embryonal (104)  ·  Neuroectodermal Tumors, Primitive (92)  ·  Neoplasms by Site (74)  ·  Glioma (72)  ·  Nervous System Diseases (67)  ·  Nervous System Neoplasms (65)  ·  Central Nervous System Diseases (43)  ·  Brain Diseases (42)  ·  Neoplasms, Connective and Soft Tissue (33)

Interventions

Cyclophosphamide (20)  ·  Temozolomide (17)  ·  Cisplatin (14)  ·  Etoposide (14)  ·  Radiotherapy (14)  ·  Carboplatin (11)  ·  Vincristine (11)  ·  Irinotecan (10)  ·  Magnetic Resonance Spectroscopy (10)  ·  Filgrastim (9)  ·  Lomustine (6)  ·  Peripheral Blood Stem Cell Transplantation (6)  ·  Phantoms, Imaging (6)  ·  X-Rays (6)  ·  Bevacizumab (5)

Sponsors

National Cancer Institute (NCI) (25)  ·  Children's Oncology Group (4)  ·  Duke University (4)  ·  St. Jude Children's Research Hospital (4)  ·  Sue O'Dorisio (4)  ·  Giselle Sholler (3)  ·  Gustave Roussy, Cancer Campus, Grand Paris (3)  ·  Pediatric Brain Tumor Consortium (3)  ·  Eli Lilly and Company (2)  ·  Herbert Irving Comprehensive Cancer Center (2)  ·  Memorial Sloan Kettering Cancer Center (2)  ·  Nationwide Children's Hospital (2)  ·  Novartis Pharmaceuticals (2)  ·  Pfizer (2)  ·  Washington University School of Medicine (2)

Countries

United States (87)  ·  Canada (19)  ·  Puerto Rico (19)  ·  Australia (18)  ·  France (16)  ·  Spain (13)  ·  Italy (10)  ·  United Kingdom (10)  ·  Germany (9)  ·  Switzerland (9)  ·  Netherlands (7)  ·  China (4)  ·  Denmark (4)  ·  New Zealand (4)  ·  Sweden (4)

Top investigators

Darell D. Bigner, MD, PhD (3)  ·  Amar Gajjar (2)  ·  Charles S. Hesdorffer, MD (2)  ·  Giselle Sholler, MD (2)  ·  Maryam Fouladi (2)  ·  Maryam Fouladi, MD (2)  ·  Adam S Levy (1)  ·  Aditi Bagchi, MD, PhD (1)  ·  Alice Lee (1)  ·  Alok Kothari, M.D. (1)  ·  Amar Gajjar, MD (1)

Results publications

PMID 31401903, PMID 26169613, PMID 40073837, PMID 40721826, PMID 40967259, PMID 11835236, PMID 16408203, PMID 16532433, PMID 16549835, PMID 17019740, PMID 17610262, PMID 18447671, PMID 18623206, PMID 18989154, PMID 20943374, PMID 28153957, PMID 29181270, PMID 31838007, PMID 33025730, PMID 33591402, PMID 33823018, PMID 34168987, PMID 34171339, PMID 34486544, PMID 34540703, PMID 35353553, PMID 35395680, PMID 36291912, PMID 37883081, PMID 38815151, PMID 38935895, PMID 39298716, PMID 40086048, PMID 41166674, PMID 42686334, PMID 42788739, PMID 42853672, PMID 42867148

NIH funding

U10CA180886 (15), U10CA098543 (5), U01CA081457 (4), R01CA167632 (3), UM1CA081457 (3), 2023 (2), 2016 (1), 2019 (1), P30CA008748 (1), P30CA022453 (1), P30CA033572 (1), P30CA086862 (1), P30CA124435 (1), R01CA187079 (1), R01CA229646 (1)